EVRYSDI

This brand name is authorized in United States. It is also authorized in Brazil, Croatia, Ecuador, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, New Zealand, Poland, Romania, Spain, UK.

Active ingredients

The drug EVRYSDI contains one active pharmaceutical ingredient (API):

1	Risdiplam UNII 76RS4S2ET1 - RISDIPLAM
	Risdiplam is a survival of motor neuron 2 (SMN2) pre-mRNA splicing modifier designed to treat SMA caused by mutations of the SMN1 gene in chromosome 5q that lead to SMN protein deficiency. Functional SMN protein deficiency is directly linked to the SMA pathophysiology which includes progressive loss of motor neurons and muscle weakness. Risdiplam treats SMA by increasing and sustaining functional SMN protein levels.
	Read more about Risdiplam

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EVRYSDI Powder for oral solution	MPI, EU: SmPC	European Medicines Agency (EU)
EVRYSDI Oral solution	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M09AX10		M Musculo-skeletal system → M09 Other drugs for disorders of the musculo-skeletal system → M09A Other drugs for disorders of the musculo-skeletal system → M09AX Other drugs for disorders of the musculo-skeletal system
Discover more medicines within M09AX10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	529221030027002
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	6376-MEE-0621
EE	Ravimiamet	1845446
ES	Centro de información online de medicamentos de la AEMPS	1211531001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	573248
GB	Medicines & Healthcare Products Regulatory Agency	397636
HK	Department of Health Drug Office	67230
IL	מִשְׂרַד הַבְּרִיאוּת	8768
JP	医薬品医療機器総合機構	1190029R1028
LT	Valstybinė vaistų kontrolės tarnyba	1092319
NZ	Medicines and Medical Devices Safety Authority	21894
PL	Rejestru Produktów Leczniczych	100450142
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67547001
US	FDA, National Drug Code	50242-175